Coya Therapeutics, INC 8-K filings

Coya Therapeutics announced its first quarter 2024 financial results, highlighted by an expanded clinical pipeline and progress in regulatory discussions.

Coya Therapeutics' stockholders approved an amendment to the company's 2021 Equity Incentive Plan, increasing the number of shares available for issuance by 750,000 to a total of 2,571,070.

Coya Therapeutics announced its 2023 financial results and provided a corporate update, highlighting progress in its clinical programs and strategic collaborations.

Coya Therapeutics reports a cash balance of $32.6 million as of December 31, 2023, and received a $7.5 million milestone payment in January 2024, boosting its pro forma cash position to $40.1 million.